Clinical Manifestations and Risk Factors of Liver Injury Induced by PD-1 Inhibitors in Patients with Malignancies: A Case-Control Study
In clinical therapy, close monitoring of liver function is recommended, especially for patients with baseline ALT≥19.5 U/L, AST≥19.5 U/L, and GGT≥28.5 U/L during immunotherapy with PD-1 inhibitors.
Authors
- Pengfei Zhao (ORCID: https://orcid.org/0000-0002-5154-8223)
- Wenming Ma
- Lihong Yu (ORCID: https://orcid.org/0000-0002-0874-3998)
- Ting Zhao (ORCID: https://orcid.org/0000-0002-1452-5831)
Institutions
- Weifang People's Hospital (CN)
Publication Details
- Journal
- Therapeutics and Clinical Risk Management
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/tcrm.s510973
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14